Opportunity Information: Apply for PAR 10 003
Apply for PAR 10 003
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012 (P50)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.397 Cancer Centers Support Grants 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
- This funding opportunity was created on Oct 2, 2009 and posted on Oct 2, 2009.
- Applicants must submit their applications by Sep 20, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,500,000.00 to eligible and selected applicants.
- Eligible applicants include: State governments Public and State controlled institutions of higher education Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Regional Organizations U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012 (P50) opportunity (Funding Opportunity Number PAR-10-003) was a National Institutes of Health (NIH) funding announcement led by the National Cancer Institute (NCI), with participation from the National Institute of Dental and Craniofacial Research (NIDCR) and the National Institute of Neurological Disorders and Stroke (NINDS). Posted on October 2, 2009, it invited both new and competing renewal applications for P50 Specialized Center Grants to run for five years. The central goal was to support high-impact, investigator-initiated research programs that could measurably improve the detection, diagnosis, treatment, and prevention of organ-specific cancers (or closely related groups of cancers), with an explicit expectation that funded centers would operate at the cutting edge of translational cancer research.
A defining feature of this SPORE announcement was its strict emphasis on translational science grounded in human biology. Projects were expected to move discoveries toward clinical use, and that translation had to be anchored in knowledge derived from studies of human disease biology, including cellular, molecular, structural, biochemical, and genetic approaches. In practical terms, the program was designed to fund research that connects mechanistic understanding of human cancer to tangible clinical advances, such as better screening approaches, more accurate diagnostic strategies, improved therapies, and effective prevention methods. The announcement also made clear that SPOREs were not meant to fund isolated projects; they were intended to support integrated, collaborative programs capable of sustaining a pipeline from laboratory insights to patient-oriented outcomes.
Beyond the research aims, the opportunity described SPOREs as centers expected to build and strengthen shared infrastructure and collaborative capacity. Applicants were expected to conduct a wide spectrum of research activities while also contributing significantly to the development of specialized research cores (COREs), improved research model systems, and collaborative research projects that could include partnerships with other institutions. This reflects the SPORE model as a team-science structure: rather than funding only independent investigators, the P50 mechanism supports coordinated programs that share resources, harmonize methods, and encourage cross-disciplinary collaboration to accelerate translation. The emphasis on core development and model systems also signals that grantees were expected to leave behind durable capabilities that extend beyond individual studies, such as shared biostatistics, biospecimen resources, imaging, pathology, or other specialized platforms that enable multiple translational projects to progress efficiently.
The mechanism of support for this opportunity was the NIH P50 specialized center grant. The announcement anticipated funding roughly 10 to 20 new SPORE awards per year, though awards were explicitly contingent on the availability of funds and the receipt of a sufficient number of meritorious applications. The listing reported an estimated total funding figure of $2,500,000, and it stated there was no cost sharing or matching requirement. The overall opportunity was categorized as discretionary funding, and the funding activity category was aligned with education and health. The opportunity also mapped to several CFDA program areas reflecting its cross-cutting cancer and biomedical scope, including oral diseases and disorders research (93.121), multiple cancer research areas spanning prevention, detection/diagnosis, treatment, and biology (93.393 through 93.396), cancer center support grants (93.397), and extramural neuroscience and neurological disorders programs (93.853), consistent with the involvement of NCI, NIDCR, and NINDS.
Eligibility under PAR-10-003 was broad and included a wide range of domestic organizational types that could credibly host a large, multi-project translational research center. Eligible applicants included state governments; public and state-controlled institutions of higher education; private institutions of higher education; small businesses; for-profit organizations (other than small businesses); and nonprofit organizations, including those with and without 501(c)(3) IRS status (with distinctions noted for those that are not institutions of higher education). Additional eligible applicants also included certain federal government agencies, regional organizations, and U.S. territories or possessions. This breadth reflects the SPORE program’s interest in supporting strong translational ecosystems wherever they exist, while still requiring applicants to demonstrate the scientific depth, clinical integration, and infrastructure needed to run an organ-focused translational cancer center.
In terms of timing, the announcement was created and posted on October 2, 2009, and it remained open through a final closing date of September 20, 2012, with an archive date of October 21, 2012. In other words, it covered submission cycles across the 2010, 2011, and 2012 years, aligning with the title of the opportunity. Applicants seeking the full details were directed to the NIH grants page for PAR-10-003, and contact information was provided for the NIH Office of Extramural Research (OER) web support for access or linking issues. Overall, PAR-10-003 was structured to fund high-performing, organ-specific translational cancer research centers that combine multiple coordinated projects with shared cores and collaborative networks, with the explicit objective of producing clinically meaningful advances rooted in human cancer biology.
Frequently Asked Questions (FAQs)
What is the PAR-10-003 funding opportunity?
PAR-10-003 is a National Institutes of Health (NIH) funding announcement for the Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012. It invited applications for P50 Specialized Center Grants focused on organ-specific (or closely related groups of) cancers, with a strong emphasis on translational cancer research grounded in human biology.
Which NIH Institutes participated in this opportunity?
The announcement was led by the National Cancer Institute (NCI), with participation from the National Institute of Dental and Craniofacial Research (NIDCR) and the National Institute of Neurological Disorders and Stroke (NINDS).
What type of grant mechanism was used?
This opportunity used the NIH P50 specialized center grant mechanism (P50 Specialized Center Grants), which is designed to support coordinated, multi-project center programs.
What was the central goal of the SPORE program under this announcement?
The central goal was to support high-impact, investigator-initiated research programs expected to measurably improve the detection, diagnosis, treatment, and prevention of organ-specific cancers (or closely related groups of cancers), operating at the cutting edge of translational cancer research.
What does "translational" mean in the context of this SPORE announcement?
In this announcement, translational research meant moving discoveries toward clinical use, and doing so using knowledge derived from studies of human cancer biology. The expectation was that research would connect mechanistic understanding of human disease to tangible clinical advances such as improved screening, diagnostics, therapies, and prevention approaches.
What was the defining scientific emphasis of this SPORE opportunity?
A defining feature was a strict emphasis on translational science grounded in human biology. Studies were expected to be anchored in human disease biology using approaches such as cellular, molecular, structural, biochemical, and genetic methods.
Were SPOREs intended to support isolated, independent projects?
No. The announcement made clear that SPOREs were not intended to fund isolated projects. They were designed to support integrated, collaborative programs capable of sustaining a pipeline from laboratory insights to patient-oriented outcomes.
What kinds of improvements were SPORE-funded centers expected to deliver?
Funded centers were expected to produce clinically meaningful advances, including better detection and screening approaches, more accurate diagnostic strategies, improved treatments, and effective prevention methods, rooted in human cancer biology.
What role did shared infrastructure and cores play in this program?
SPOREs were expected to build and strengthen shared infrastructure and collaborative capacity. The opportunity emphasized the development of specialized research cores (COREs), improved research model systems, and collaborative research efforts to accelerate translational progress across multiple projects.
Could SPORE collaborations include partnerships beyond a single institution?
Yes. The opportunity described collaborative research projects that could include partnerships with other institutions, reflecting a team-science structure and coordinated networks.
What was the anticipated project period for awards?
The announcement invited P50 Specialized Center Grant applications intended to run for five years.
How many new SPORE awards were anticipated each year?
The announcement anticipated roughly 10 to 20 new SPORE awards per year, contingent on the availability of funds and the receipt of a sufficient number of meritorious applications.
Was funding guaranteed?
No. Awards were explicitly contingent on the availability of funds and the receipt of meritorious applications.
What funding amount was referenced in the listing?
The listing reported an estimated total funding figure of $2,500,000.
Was cost sharing or matching required?
No. The announcement stated there was no cost sharing or matching requirement.
How was this opportunity categorized in terms of funding type and activity area?
The opportunity was categorized as discretionary funding, and the funding activity category aligned with education and health.
Which organizations were eligible to apply?
Eligibility was broad and included state governments; public and state-controlled institutions of higher education; private institutions of higher education; small businesses; for-profit organizations (other than small businesses); and nonprofit organizations (including those with and without 501(c)(3) IRS status, with distinctions noted for those that are not institutions of higher education). It also included certain federal government agencies, regional organizations, and U.S. territories or possessions.
What kinds of applicants does this breadth of eligibility reflect?
It reflects the SPORE program's intent to support strong translational ecosystems wherever they exist, while still requiring applicants to demonstrate the scientific depth, clinical integration, and infrastructure needed to run an organ-focused translational cancer center.
When was the opportunity posted and what was the application window?
The announcement was posted on October 2, 2009. It remained open through a final closing date of September 20, 2012, and had an archive date of October 21, 2012.
Which years of submission cycles did the announcement cover?
It covered submission cycles across the 2010, 2011, and 2012 years, consistent with the opportunity title.
Where were applicants directed for full details and official instructions?
Applicants were directed to the NIH grants page for PAR-10-003 for full details.
Who was listed for support related to access or linking issues?
Contact information was provided for the NIH Office of Extramural Research (OER) web support for access or linking issues.
What CFDA program areas were associated with this opportunity?
The opportunity mapped to multiple CFDA program areas reflecting cancer and biomedical scope, including oral diseases and disorders research (93.121); multiple cancer research areas spanning prevention, detection/diagnosis, treatment, and biology (93.393 through 93.396); cancer center support grants (93.397); and extramural neuroscience and neurological disorders programs (93.853).
Why do CFDA areas include oral health and neurological programs in a cancer SPORE announcement?
The CFDA mapping reflects the cross-cutting scope of the program and the participation of NCI, NIDCR, and NINDS.
What was the expected scientific positioning of funded centers?
Funded centers were expected to operate at the cutting edge of translational cancer research, integrating human biology insights with efforts that can advance toward clinical application.
What was the SPORE model trying to leave behind beyond individual studies?
The emphasis on shared cores, model systems, and coordinated programs signals an expectation that grantees would build durable capabilities and collaborative infrastructure that can support multiple translational projects efficiently.
Browse more opportunities from the same category: Education Health
Next opportunity: Saudi Arabia Womens Civic Participation, Judicial Engagement, and Governance and Public Management Fellowships
Previous opportunity: 2010 NATIONAL NON PROFIT ORGANIZATION RECREATIONAL BOATING SAFETY GRANT PROGRAM
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 10 002 Funding Number: PAR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 10 001 Funding Number: PAR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Community Networks Program (CNP) Centers for Reducing Cancer Disparities through Outreach, Research and Training (U54) Apply for RFA CA 09 032 Funding Number: RFA CA 09 032 Agency: National Institutes of Health Category: Education Health Funding Amount: $900,000 |
| Pathway to Independence Award in Cancer Nanotechnology Research (K99/R00) Apply for RFA CA 09 015 Funding Number: RFA CA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Nanotechnology Training Centers (CNTCs)(R25) Apply for RFA CA 09 014 Funding Number: RFA CA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 10 012 Funding Number: PA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 10 011 Funding Number: PA 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 10 013 Funding Number: PA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33) Apply for RFA CA 10 002 Funding Number: RFA CA 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Application and Early Stage Development of Emerging Technologies in Cancer Research (R21) Apply for RFA CA 10 003 Funding Number: RFA CA 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Innovative Technology Development for Cancer Research (R21) Apply for RFA CA 10 005 Funding Number: RFA CA 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Cancer Research (R33) Apply for RFA CA 10 004 Funding Number: RFA CA 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science (R21) Apply for RFA CA 10 001 Funding Number: RFA CA 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Epidemiology, Prevention, and Treatment Research Data (R01) Apply for PAR 10 018 Funding Number: PAR 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and/or Women and Sex/Gender Differences (R36) Apply for PAR 10 020 Funding Number: PAR 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| AIDS Science Track Award for Research Transition (R03) Apply for PAR 10 021 Funding Number: PAR 10 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| State and Community Tobacco Control Policy and Media Research (U01) Apply for RFA CA 10 008 Funding Number: RFA CA 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effectiveness Research on Smoking Cessation in Hospitalized Patients (U01) Apply for RFA HL 10 020 Funding Number: RFA HL 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01) Apply for PA 10 025 Funding Number: PA 10 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R21) Apply for PA 10 026 Funding Number: PA 10 026 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
